In this issue of JAMA, Rollman et al report concerning findings regarding US Food and Drug Administration (FDA) stewardship of the Risk Evaluation and Mitigation Strategies (REMS) system,1 raising further uncertainty as to its utility in ensuring the safe use of prescription drugs. Created under the 2007 FDA Amendments Act, this system was intended to address the FDA’s limited powers over approved drugs, authorizing the agency to require manufacturers to develop and implement REMS for drugs or drug classes posing special safety risks. Components of REMS may include a lay medication guide for patients, a communication plan for physicians, and—for drugs posing the greatest risks—elements to assure safe use (ETASU), such as volume restrictions on dispensing, mandatory physician training and certification, and patient enrollment in a registry.
Sarpatwari A, Curfman G. Mitigating Health Risks of Prescription Drugs: Lessons From FDA Oversight of Opioid Products. JAMA. 2019;321(7):651–653. doi:10.1001/jama.2019.0236
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: